About 13 results found for searched term "PPARγ-IN-2" (0.131 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41589 | PPARγ-IN-2 | PPAR |
| PPARγ-IN-2 is a PPARγ inhibitor. | ||
| M1602 | SR1664 | PPAR |
| SR 1664 | ||
| SR1664 is an antidiabetic compound that binds to PPARγ and can effectively inhibit CDK5-mediated phosphorylation of PPARγ with IC50 of 80 nM and Ki of 28.67 nM. | ||
| M4275 | Oleuropein | PPAR |
| Oleuropein, found in olive leaves and oils, exerts antioxidant, anti-inflammatory and antiatherosclerotic effects by directly inhibiting PPARγ transcriptional activity. Oleuropein induces apoptosis of breast cancer cells through p53-dependent pathways and regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase. | ||
| M5371 | 5-Aminosalicylic acid | NF-κB |
| Mesalamine; 5-ASA; Mesalazine | ||
| 5-aminosalicylic acid (Mesalamine) is a specific PPARγ agonist that also inhibits P21-activated kinase 1 (PAK1) and NF-κB. | ||
| M8040 | SC-236 | COX |
| Sc-236 is a COX-2 specific inhibitor with an IC50 value of 10 nM for COX-1 and a PPARγ agonist with oral activity. Sc-236 inhibits activator protein-1 (AP-1) activity by c-Jun amino terminus. Sc-236 exerts anti-inflammatory effects by inhibiting ERK phosphorylation in mouse models. | ||
| M9195 | Saroglitazar | PPAR |
| Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity, with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. | ||
| M13724 | Saroglitazar Magnesium | PPAR |
| Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. | ||
| M21176 | Leriglitazone | PPAR |
| Hydroxypioglitazone | ||
| Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) is a PPARγ agonist that provides high transcriptional potency by stabilizing the PPARγ (AF-2) coactivator binding surface and enhancing coactivator binding capacity. Leriglitazone (Hydroxypioglitazone) binds to PPARγC (LBD) with a Ki value of 1.2 μM and induces PPARγ (LBD) transcriptional efficiency with an EC50 of 680 nM. | ||
| M29032 | FK614 | PPAR |
| FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes. | ||
| M29067 | Farglitazar | PPAR |
| GI262570; GI262570X | ||
| Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients. | ||
| M29897 | AMG131 | PPAR |
| INT131 | ||
| AMG131 (INT131), a potent and highly selective PPARγ partial agonist, binds to PPARγ and displaces Rosiglitazone with a Ki of ~10 nM. AMG131 can be used for research of type-2 diabetes mellitus (T2DM). | ||
| M38943 | Caulophyllogenin | PPAR |
| Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation. | ||
| M55660 | MTX-531 | EGFR/HER2 |
| MTX531 | ||
| MTX-531 is a first-in-class, potent and selective inhibitor of EGFR and PI3K, with IC50s of 14.7 nM and 1.1-233 nM (differ in subtype). MTX-531 can also act as a weak agonist of PPARγ, with the EC50 of 3.4 μM in 293H cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
